Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
AtriCure Swings to Q3 Adjusted Earnings as Revenue Rises; Shares Drop After Hours

AtriCure Swings to Q3 Adjusted Earnings as Revenue Rises; Shares Drop After Hours

MT newswireMT newswire2026/11/03 20:34
04:34 PM EST, 11/03/2026 (MT Newswires) -- AtriCure (ATRC) reported Q3 adjusted earnings late Tuesday of $0.17 per diluted share, swinging from the loss of $0.01 a year earlier. Analysts polled by FactSet expected adjusted earnings of $0.02. Revenue in the three months ended Sept. 30 rose to $154.5 million from $134.3 million a year earlier. Analysts expected $151.1 million. The company raised full-year adjusted EPS guidance to $0.40 to $0.46 from the prior forecast of $0.24 to $0.32. Analysts expect $0.29. AtriCure expects full-year revenue of $606 million to $610 million, compared with the previous outlook of $602 million to $610 million. Analysts expect $606.2 million. AtriCure shares fell 4% in after-hours trading.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny